Clinical Trials

124 enrolled

NSCLC

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT05888402 2026-02-27

InTRist

50 enrolled

Local Advanced Non-small Cell Lung Cancer

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled

Phase 2 Active not recruiting

NSCLC

NCT06293690 2025-12-18

Toripalimab Combined With SBRT for NSCLC

40 enrolled

Non-small Lung Cancer

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05386888 2025-10-02

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Phase 2 Completed

65 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06623136 2025-09-26

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06127303 2025-09-05

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07039656 2025-08-07

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

211 enrolled

Stage IB-IIIB NSCLC

NCT07097948 2025-08-01

Adjuvant

40 enrolled

Recurrence, Small Cell Lung Carcinoma

NCT03623776 2024-12-06

NAJSCR

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT06648200 2024-10-18

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

100 enrolled

Recurrence, Small Cell Lung Carcinoma

NCT06256237 2024-05-29

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Small Cell Lung Carcinoma

NCT04238169 2024-02-28

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

Phase 2 Completed

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06065813 2023-10-04

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05962021 2023-08-01

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

126 enrolled

Non Squamous Non Small Cell Lung Cancer

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

124 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent

NCT05800340 2023-04-05

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05212922 2023-03-20

YH001

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05162196 2022-05-02

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

57 enrolled

Small Cell Lung Carcinoma

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04304248 2021-05-06

NeoTAP01

Carcinoma, Non-Small-Cell Lung

NCT04725448 2021-04-06

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms

NCT04713761 2021-01-26

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

15 enrolled

Mesothelioma, Malignant

NCT04613804 2020-11-03

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Carcinoma, Non-Small-Cell Lung

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

60 enrolled

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT03848611 2020-07-09

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03904719 2020-07-09

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

20 enrolled